Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Martin HutchingsFranck MorschhauserGloria IacoboniCarmello Carlo-StellaFritz C OffnerAnna SuredaGilles Andre SallesJoaquín Martínez-LopezMichael CrumpDenise N ThomasPeter N MorcosCristiano FerliniAnn-Marie E BröskeAnton BelousovMarina BacacNatalie DimierDavid J CarlileLinda LundbergDavid Perez-CallejoPablo UmañaTom MooreMartin WeisserMichael J DickinsonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In patients with predominantly refractory, aggressive B-NHL, glofitamab showed favorable activity with frequent and durable CRs and a predictable and manageable safety profile.